Jeremy Richard Graff

机构：United Therapeutics (United States), Io Therapeutics (United States)

发表论文 154 篇 · 总被引 18698 次 · h-index 44

代表论文

• Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies (2022 · Frontiers in Oncology · 被引 21)
• Abstract 2454: A Drug Response Predictor (DRP®) is associated with enhanced overall survival in the phase 2 trial in advanced, recurrent ovarian cancer patients treated twice daily with 2X-121/ Stenoparib (NCT03878849) (2026 · Cancer Research)
• Abstract 4576: 2X-121/ stenoparib - a novel, dual inhibitor of PARP and tankyrase in phase 2 clinical trials in advanced ovarian cancer- blocks the WNT signaling pathway and inhibits growth of human colorectal cancer cell lines at clinically relevant drug concentrations (2026 · Cancer Research)
• Abstract A030: 2X-121, a novel, dual inhibitor of PARP and tankyrase, shows promising clinical benefit in a phase 2 trial in advanced, recurrent ovarian cancer patients (NCT#03878849) (2025 · Cancer Research)
• A phase II trial of stenoparib (2×-121): A novel dual tankyrase and poly (ADP-ribose) polymerase inhibitor in advanced, recurrent ovarian cancer (2025 · Gynecologic Oncology)
• Abstract 725: An mRNA-based predictor of response to daratumumab in multiple myeloma (2025 · Cancer Research)